AAAAAA

   
Results: 1-3 |
Results: 3
A National Cancer Institute of Canada Clinical Trials Group phase II studyof eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer
Authors: Knowling, M Browman, G Siu, L Khoo, K Cooke, A Tannock, I Klaassen, D Cripps, C Goss, G Matthews, S Clarke, R Seymour, L
Citation: M. Knowling et al., A National Cancer Institute of Canada Clinical Trials Group phase II studyof eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer, ANN ONCOL, 12(7), 2001, pp. 919-922
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies
Authors: Eckhardt, SG Baker, SD Britten, CD Hidalgo, M Siu, L Hammond, LA Villalona-Calero, MA Felton, S Drengler, R Kuhn, JG Clark, GM Smith, SL MacDonald, JR Smith, C Moczygemba, J Weitman, S Von Hoff, DD Rowinsky, EK
Citation: Sg. Eckhardt et al., Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies, J CL ONCOL, 18(24), 2000, pp. 4086-4097
Combined modality therapy for elderly patients with limited small cell lung cancer
Authors: Shepherd, FA Payne, DG Feld, R Murray, N Siu, L Quon, H Pater, J Zee, B
Citation: Fa. Shepherd et al., Combined modality therapy for elderly patients with limited small cell lung cancer, TREATMENT OPTIMIZATION FOR LUNG CANCER, 1998, pp. 249-259
Risultati: 1-3 |